UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies
Authors:
- 29 August 2023
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 24 (9) , 963-966
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020International Journal of Cancer, 2023
- Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug DevelopmentCancer Discovery, 2022
- Project Orbis: the UK experience after 1 yearThe Lancet Oncology, 2022
- Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019JAMA Network Open, 2022
- The value of anticancer drugs — a regulatory viewNature Reviews Clinical Oncology, 2021
- Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau DiseaseNew England Journal of Medicine, 2021
- Project Orbis: Global Collaborative Review ProgramClinical Cancer Research, 2020
- Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EUBMJ Open, 2019
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidanceBMJ Open, 2013